Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Longer treatment with vismodegib lowers relapse risk in basal cell carcinoma.

Radiotherapy is a good option when further surgery for skin cancer isn't preferred, but more research is needed to compare it with other methods.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Early detection and intervention improve survival in melanoma patients.

Patients prioritize quality of life, overall survival, and progression-free survival in treatment decisions for advanced breast cancer.

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

Valproic acid helps delay hair loss and increases survival time for high-grade glioma patients undergoing radiation therapy.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Temozolomide improves survival in grade III glioma patients without harming quality of life.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

The treatment improved survival and controlled cancer spread but required managing side effects like rashes.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Removing lymph nodes does not improve survival for advanced ovarian cancer and may cause more complications.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

The combination treatment showed a higher response rate but no significant survival benefits.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Pegylated liposomal doxorubicin is as effective as conventional doxorubicin but causes fewer heart problems and side effects.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Ripretinib is effective and safe for treating advanced GIST in Chinese patients, particularly for non-gastric GISTs.

EGFR inhibitors for lung cancer can cause severe skin issues.

Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.

Repurposing existing drugs can improve cancer treatment but faces challenges.